Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
Creative Medical Technology Creative Medical Technology (US:CELZ) Globenewswire·2026-01-13 22:15

Data Show Strong Functional and Pain Improvements Supported by Excellent Safety ProfilePHOENIX, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced positive interim 180-day follow-up data from its FDA-cleared ADAPT clinical trial evaluating CELZ-201 (Olastrocel), the Company’s proprietary perinatal tissue-derived cell therapy for chr ...